Study summary

Zanubrutinib gave deeper responses than ibrutinib with fewer heart side effects

ASPEN trial (final analysis) · 229 people, phase 3 · Published November 2023, Journal of Clinical Oncology

36.3%very good partial or complete response with zanubrutinib, vs 25.3% with ibrutinib

What was tested

Zanubrutinib against ibrutinib, two daily BTK inhibitor pills, for symptomatic Waldenström macroglobulinemia.

What they found

What it means

Made zanubrutinib a preferred BTK inhibitor for WM.

J Clin Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.